CYCLO THERAPEUTICS INC (CYTH)

US23254X2018 - Common Stock

1.21  -0.01 (-0.82%)

After market: 1.2 -0.01 (-0.83%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025
Revenue
YoY % growth
1.59M
76.67%		1.38M
-13.21%		1.076M
-22.00%		3.368M
212.89%
EBITDA
YoY % growth
-14.27M
-59.44%		-15.6M
-9.32%		-20.031M
-28.40%		N/AN/A
EBIT
YoY % growth
-14.29M
-59.49%		-15.62M
-9.31%		-20.05M
-28.36%		-24.15M
-20.45%
Operating Margin
-898.74%-1,131.88%-1,862.68%-717.03%
EPS
YoY % growth
-2.30-1.83
20.43%		N/A-1.07

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2023
Q2Q % growth		 -0.33
19.51%		-0.450.1226.47%
Q1 2023
Q2Q % growth		 -0.46
-39.39%		-0.43-0.03-7.38%
Q4 2022
Q2Q % growth		 -0.59
-55.26%		-0.26-0.33-131.37%
Q3 2022
Q2Q % growth		 -0.50
16.67%		-0.540.047.51%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 311.4K
63.89%		454.92K-143.52K-31.55%
Q3 2023
Q2Q % growth		 495.48K
10.11%		437.58K57.9K13.23%
Q2 2023
Q2Q % growth		 120K
-77.78%		403.92K-283.92K-70.29%
Q1 2023
Q2Q % growth		 150K
-21.05%		387.6K-237.6K-61.30%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A 0% 0%
RevenueN/A N/A 0% 0%